DOI: 10.1093/ofid/ofag487 ISSN: 2328-8957
Similar Efficacy, Safety, and Immune Improvement Through 96 Weeks in Individuals With Limited HIV-1 Treatment Options Using Twice-Daily Dolutegravir- or Fostemsavir-Based Regimens
Antonella Castagna, Iacopo Marcon, Fangfang Du, Bo Li, Marcia Wang, Andrew Clark, Cynthia Donovan, Bryn Jones, Manyu PrakashAbstract
Constructing suppressive regimens for individuals with multidrug-resistant HIV-1 can be challenging. Separate analyses of 96-week outcomes from the phase 3 VIKING-3 and BRIGHTE studies demonstrate that twice-daily dolutegravir-based and fostemsavir-based regimens each provide robust viral suppression, favorable safety profiles, and CD4+ T-cell count improvement in this population.